Asymptomatic premalignant plasma cell disorder with monoclonal protein <3 g/dL, marrow plasma cells <10%, no end-organ damage.
🔒 Free preview limit reached
Keep reading — start your free trial
You've read your 2 free diagnosis previews. Create your free account to unlock the full Monoclonal Gammopathy of Undetermined Significance (MGUS) outline — plus all 514 diagnoses, 3,500+ board-style questions, flashcards, and an AI tutor. Your 7-day free trial includes everything, and there's no credit card required.
Free to start · No credit card · Cancel anytime
Risk factors
- Advancing age
- Black race / African ancestry
- Male sex
- Family history of MGUS or multiple myeloma
- Exposure to pesticides, herbicides, ionizing radiation
- Chronic immune stimulation — autoimmune disease, HIV, HCV
Pathophysiology
Clonal plasma cells in the bone marrow produce a homogeneous immunoglobulin (M-protein). Unlike multiple myeloma, the clone has not acquired the additional genetic hits required to produce overt malignancy with end-organ injury. Cytogenetic abnormalities (IgH translocations involving 11q13, 4p16, 16q23; trisomies; del 17p) are similar to MM, suggesting MGUS is a true precursor.
Clinical presentation
Symptoms
- Asymptomatic — typically discovered incidentally on workup for elevated total protein, neuropathy, or unrelated illness
- Rarely associated symptoms: peripheral neuropathy (especially IgM MGUS with anti-MAG antibodies)
Signs / physical exam
- No specific findings
- No anemia, lytic lesions, renal dysfunction, or hypercalcemia attributable to MGUS
- Possible findings of underlying associated condition (e.g., neuropathy in IgM MGUS)
Classic findings
Incidental M-spike on serum protein electrophoresis (SPEP) in an asymptomatic older adult.
Differential diagnosis
- Multiple myeloma — M-protein ≥3 g/dL, marrow plasma cells ≥10%, AND end-organ damage (CRAB) or biomarkers (≥60% plasma cells, FLC ratio ≥100, MRI focal lesions ≥2)
- Smoldering multiple myeloma — M-protein ≥3 g/dL OR marrow plasma cells 10-60% WITHOUT CRAB or biomarkers
- Waldenström macroglobulinemia — IgM M-protein + lymphoplasmacytic infiltrate; MYD88 L265P mutation
- Light chain amyloidosis (AL) — Cardiac, renal, neuropathic involvement; Congo red-positive amyloid on biopsy; abnormal FLC ratio
- POEMS syndrome — Polyneuropathy, organomegaly, endocrinopathy, M-protein, skin changes; elevated VEGF
- Solitary plasmacytoma — Single bone or extramedullary lesion; marrow uninvolved
Diagnostic workup
Diagnostic criteria
IMWG criteria — ALL three required:
1) Serum M-protein <3 g/dL
2) Clonal bone marrow plasma cells <10%
3) Absence of myeloma-defining events: hypercalcemia, renal dysfunction, anemia, bone lesions (CRAB); plus absence of amyloidosis or other plasma cell disorder. Subtypes: non-IgM MGUS (IgG, IgA), IgM MGUS, and light chain MGUS.
Labs
- Serum protein electrophoresis (SPEP) with immunofixation (IFE) — identify and quantify M-protein
- Serum free light chain (FLC) assay with kappa/lambda ratio — abnormal ratio is a risk factor for progression
- Quantitative immunoglobulins (IgG, IgA, IgM) — assess for immunoparesis (suppression of uninvolved Igs)
- CBC, BMP, calcium, albumin, LDH, beta-2 microglobulin — assess for CRAB criteria
- Urine protein electrophoresis (UPEP) with immunofixation, 24-h urine — assess for light chain (Bence Jones) proteinuria
- Bone marrow biopsy if M-protein ≥1.5 g/dL, non-IgG isotype, abnormal FLC ratio, or unexplained cytopenias/symptoms
Imaging
- Whole-body low-dose CT, MRI, or PET-CT to evaluate for lytic lesions if intermediate/high-risk MGUS, IgA or light chain isotype, or symptomatic — replaces traditional skeletal survey
- Cardiac MRI / echocardiogram if amyloidosis suspected (NT-proBNP, troponin, FLC ratio)
Treatment
First-line
- NO TREATMENT — observation only
- Risk-stratified surveillance based on Mayo Clinic risk model (non-IgG isotype, M-protein ≥1.5 g/dL, abnormal FLC ratio)
- 0 risk factors (low risk) — repeat SPEP in 6 months, then every 2-3 years if stable
- 1-3 risk factors (intermediate to high risk) — annual SPEP indefinitely; consider baseline bone marrow biopsy and imaging
Low-risk MGUS
- SPEP/FLC at 6 months, then every 2-3 years if stable
- Bone marrow biopsy not initially required
- Patient education re symptoms warranting earlier evaluation
Intermediate/high-risk MGUS
- Baseline bone marrow biopsy and whole-body imaging
- Annual SPEP, FLC, CBC, calcium, creatinine indefinitely
- Bisphosphonate (alendronate, zoledronic acid) for osteopenia/osteoporosis — increased fracture risk in MGUS
IgM MGUS
- Annual surveillance
- Evaluate for Waldenström macroglobulinemia and IgM-related disorders (anti-MAG neuropathy, cryoglobulinemia, cold agglutinin disease)
Second-line / adjunct
- Refer to hematology if M-protein rises, FLC ratio worsens, cytopenias develop, or CRAB features emerge
- Treat associated conditions (e.g., rituximab for symptomatic IgM-related neuropathy or cryoglobulinemia)
Complications
- Progression to multiple myeloma (~1% per year, lifelong)
- Progression to Waldenström macroglobulinemia (IgM subtype), AL amyloidosis, or B-cell lymphoma
- Increased risk of osteoporosis and fragility fractures
- Increased risk of venous thromboembolism (modest)
- Renal disease — monoclonal gammopathy of renal significance (MGRS) requires hematology evaluation despite low M-protein
PANCE pearls
- MGUS is NEVER treated with chemotherapy — only observed.
- Cumulative risk of progression is ~1% per year and does NOT decline over time — lifelong surveillance is appropriate.
- Mayo risk model uses three factors: M-protein ≥1.5 g/dL, non-IgG isotype, abnormal FLC ratio (0-3 risk factors).
- Skeletal surveys (plain films) have been replaced by whole-body low-dose CT, MRI, or PET-CT for higher-resolution lesion detection.
- Even with normal M-protein, kidney biopsy may reveal monoclonal gammopathy of renal significance (MGRS) — refer to hematology.
- IgM MGUS carries risk of Waldenström, not multiple myeloma; the surveillance focus is different.
References
- IMWG — Rajkumar SV et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 2014; 15:e538-548.
- Mayo Clinic risk model — Rajkumar SV et al. Serum free light chain ratio is an independent risk factor for progression in MGUS. Blood 2005; 106:812-817.
- NCCN — NCCN Clinical Practice Guidelines in Oncology: Multiple Myeloma (includes MGUS surveillance).
Practice Hematology questions on FirstPassPA
Turn this outline into retention. 3,500+ board-style questions with an AI tutor that explains every answer — free to start, no card required.
Start studying free →
Browse all 514 diagnoses